Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Germany (DAX) (EWG) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

iShares MSCI Germany (DAX)Trade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Germany (DAX) vs Neurocrine Biosciences Inc — how do they compare? iShares MSCI Germany (DAX) trades at $43.82, while Neurocrine Biosciences Inc trades at $157.29 (market cap $16.46B). The key difference: iShares MSCI Germany (DAX) is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.

EWGNBIX
Sector
Broad Market / FactorHealth
52-Week High
$44.56$185.50
52-Week Low
$38.08$123.10
Market Cap
$16.46B
Enterprise Value
$16.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Germany (DAX)

EWG trades at $44.04, up 0.39% today, with a bullish technical signal driven by moving averages. Key support and resistance cluster at $44. Recent news highlights European Central Bank rate decisions and German economic policies influencing regional markets.

The outlook is cautiously optimistic given technical strength, but fundamental data is unavailable. Risks include European economic volatility and energy price fluctuations. Investors should assess upcoming financial disclosures for valuation clarity.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI Germany (DAX)

EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.

Read more on EWG

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX